Carregando...
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a su...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Principais autores: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7280484/ https://ncbi.nlm.nih.gov/pubmed/32582549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00883 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|